XELOX + Bevacizumab compared to FOLFOX4 + Bevacizumab in First line Metastatic Colorectal Cancer in a Non-reimbursed Health Care System: A Cost Analysis. Acta Medica Philippina, [S. l.], v. 49, n. 2, 2015. DOI: 10.47895/amp.v49i2.988. Disponível em: https://actamedicaphilippina.upm.edu.ph/index.php/acta/article/view/988. Acesso em: 12 apr. 2025.